- Report
- May 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- February 2024
- 114 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- February 2024
- 173 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 115 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2023
- 178 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2023
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- July 2024
- 326 Pages
China
From €3818EUR$4,000USD£3,199GBP
- Report
- July 2024
- 187 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- October 2023
- 87 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2024
- 95 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Book
- August 2012
- 552 Pages

The Preventive Vaccine market is a subset of the Vaccines market, which is focused on the development and distribution of vaccines to prevent the spread of infectious diseases. Vaccines are typically administered to healthy individuals to protect them from contracting a disease, and are often used in public health initiatives to reduce the spread of disease. Vaccines are typically developed through a combination of research and clinical trials, and are then approved by regulatory bodies before they can be distributed.
The Preventive Vaccine market is highly competitive, with a range of companies involved in the development, production, and distribution of vaccines. Companies in the market include Merck & Co., GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, and Novartis. Show Less Read more